Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer

Gastric cancer is the second most prevalent cancer and the second leading cause of cancer-related death in China. The prognosis of metastatic gastric cancer is poor with a median overall survival of 8–10 months. Apatinib, an oral small-molecule, selective vascular endothelial growth factor receptor-...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shengya, Li, Linjuan, Li, Xiaofen, Wu, Qiang, Wang, Xiaohui, Huang, Yan, Hu, Haoyue, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400896/
https://www.ncbi.nlm.nih.gov/pubmed/36034835
http://dx.doi.org/10.3389/fphar.2022.888106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400896/
https://www.ncbi.nlm.nih.gov/pubmed/36034835
http://dx.doi.org/10.3389/fphar.2022.888106

Ejemplares similares